H05BX01 cinacalcet

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents

非健保收載 TFDA 在效許可證 6 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 6 張;以下列出 6 個品項(3 項有外觀照)。

無外觀照
桂皮萘乙胺鹽酸鹽
無外觀照
銳克鈣錠75毫克
無外觀照
銳克鈣錠25毫克
鈣適樂錠25毫克 外觀
鈣適樂錠25毫克
圓形 · 綠 · 刻痕:無 · 標記:CC 25 · 9 mm
鈣易清膜衣錠25毫克 外觀
鈣易清膜衣錠25毫克
圓形 · 綠 · 刻痕:無 · 標記:AX 127 / 25 · 8 mm
佑安鈣膜衣錠25毫克 外觀
佑安鈣膜衣錠25毫克
圓形 · 綠;;;綠 · 刻痕:無 · 標記:224 / NK

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 治療透析患者的次發性副甲狀腺機能亢進。
  2. 副甲狀腺拮抗劑。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 cinacalcet (商品名 CINACALCET / Cinacalcet) · 仿單更新 2026-02-18

1 INDICATIONS AND USAGE Cinacalcet tablet is a positive modulator of the calcium sensing receptor indicated for: • Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Limitations of Use : Cinacalcet tablets are not indicated for use in patients with CKD who are not on dialysis • Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). ( 1.2 ) • Hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. ( 1.3 ) 1.1 Secondary Hyperparathyroidism Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis [see Clinical Studies ( 14.1 )] . Limitations of Use: Cinacalcet tablets are not indicated for use in patients with CKD who are not on dialysis because of an increased risk of hypocalcemia [see Warnings and Precautions ( 5.1 )] . 1.2 Parathyroid Carcinoma Cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma [see Clinical Studies ( 14.2 )] . 1.3 Primary Hyperparathyroidism Cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy [see Clinical Studies ( 14.3 )] .

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。